These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Emergence of cytomegalovirus resistance to ganciclovir after oral maintenance treatment in a renal transplant recipient. Bienvenu B; Thervet E; Bedrossian J; Scieux C; Mazeron MC; Thouvenot D; Legendre C Transplant Proc; 2000 Mar; 32(2):407. PubMed ID: 10715457 [No Abstract] [Full Text] [Related]
29. Ganciclovir prophylaxis for CMV disease infrequently associated with viral resistance. AIDS Patient Care; 1995 Dec; 9(6):308. PubMed ID: 11361450 [No Abstract] [Full Text] [Related]
30. Primary cytomegalovirus disease after five years of antiviral prophylaxis. Kijpittayarit S; Deziel P; Eid AJ; Razonable RR Transplantation; 2006 Jan; 81(1):137-8. PubMed ID: 16421494 [No Abstract] [Full Text] [Related]
31. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients. Ahsan N; Holman MJ; Yang HC Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699 [TBL] [Abstract][Full Text] [Related]
32. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study. Fleming JN; Taber DJ; Weimert NA; Nadig S; McGillicuddy JW; Bratton CF; Baliga PK; Chavin KD Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921781 [TBL] [Abstract][Full Text] [Related]
33. Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti-lymphocyte globulin treatment for acute rejection. Dickenmann MJ; Kabulbayev K; Steiger J; Cathomas G; Reusser P; Tamm M Clin Microbiol Infect; 2004 Apr; 10(4):337-9. PubMed ID: 15059125 [TBL] [Abstract][Full Text] [Related]
34. The prevalence of human herpesvirus-7 in renal transplant recipients is unaffected by oral or intravenous ganciclovir. Brennan DC; Storch GA; Singer GG; Lee L; Rueda J; Schnitzler MA J Infect Dis; 2000 May; 181(5):1557-61. PubMed ID: 10823753 [TBL] [Abstract][Full Text] [Related]
35. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients. Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A; Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208 [TBL] [Abstract][Full Text] [Related]
36. Combined prophylaxis decreases incidence of CMV-associated pneumonia after lung transplantation. Solidoro P; Delsedime L; Bergallo M; Libertucci D; Ruffini E; Costa C; Rinaldi M; Amoroso A; Baldi S Transplant Proc; 2009 May; 41(4):1347-8. PubMed ID: 19460556 [TBL] [Abstract][Full Text] [Related]
37. Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. Green M; Kaufmann M; Wilson J; Reyes J Clin Infect Dis; 1997 Dec; 25(6):1344-9. PubMed ID: 9431375 [TBL] [Abstract][Full Text] [Related]
38. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790 [TBL] [Abstract][Full Text] [Related]
39. Probability of Ganciclovir Resistance in Yasri S; Wiwanitkit V Saudi J Kidney Dis Transpl; 2019; 30(4):1000-1001. PubMed ID: 31464265 [No Abstract] [Full Text] [Related]
40. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Limaye AP; Corey L; Koelle DM; Davis CL; Boeckh M Lancet; 2000 Aug; 356(9230):645-9. PubMed ID: 10968438 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]